Trial Profile
A Phase IV Enhanced Safety Surveillance Study of ACAM2000 in Military Personnel.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs ACAM 2000 (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Emergent BioSolutions; Sanofi; Sanofi Pasteur
- 25 Aug 2021 Results published in the Vaccine
- 26 Jan 2018 Status changed from active, no longer recruiting to completed.
- 16 May 2017 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.